Utility of Oligoclonal Band Testing in Differentiating Immune-Mediated From Infectious Central Nervous System Disorders.

Objective: This study aimed to evaluate the clinical utility of oligoclonal bands (OCB) in differentiating between immune and infectious diseases of the central nervous system (CNS).

Methods: The study enrolled patients hospitalized with suspected autoimmune or infectious CNS disorders between 2021 and 2023. Patients were categorized into diagnostic groups: multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), autoimmune encephalitis (AE), and viral encephalitis (VE).

Glial growth factor 2 treatment alleviates ischemia and reperfusion-damaged integrity of the blood-brain barrier through decreasing Mfsd2a/caveolin-1-mediated transcellular and Pdlim5/YAP/TAZ-mediated paracellular permeability.

The impairment of blood-brain barrier (BBB) integrity is the pathological basis of hemorrhage transformation and vasogenic edema following thrombolysis and endovascular therapy. There is no approved drug in the clinic to reduce BBB damage after acute ischemic stroke (AIS). Glial growth factor 2 (GGF2), a recombinant version of neuregulin-1β that can stimulates glial cell proliferation and differentiation, has been shown to alleviate free radical release from activated microglial cells.